Manufacturer record
C.I. Laboratories: regulatory record
Last checked 3 November 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
2 batches manufactured by C.I. Laboratories (West Bengal) were declared Not of Standard Quality between May 2021 and April 2022. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Most recent flagged batch: RPR-117, Rabeprazole Tablets I.P. 20 mg (exp Nov 2023). CDL Kolkata (CDSCO lab) found it not of standard quality: Dissolution. Listed in the April 2022 alert.
Records by type
2 records linked to C.I. Laboratories in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Rabeprazole Tablets I.P. 20 mg | Batch RPR-117Mfg Dec 2021 · Exp Nov 2023 | DissolutionDissolution | CDL KolkataCDSCO lab | Apr 2022 |
| Ramipril Tablets I.P. 2.5 mg | Batch RMP-23Mfg Aug 2020 · Exp Jul 2022 | AssayAssay | CDL KolkataCDSCO lab | May 2021 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.